RxDoctor Payments DataLook up a doctor →

Naushad Shaik, MD

Clinical Cardiac Electrophysiology · Kissimmee, FLNPI 1447436126

Payments from drug & device makers

$1,099,858in general payments, 2019–2025

Across 2,265 payments — averaging $485.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$545K
  • Biotronik Inc.$262K
  • Acutus Medical, Inc.$81K
  • Medical Device Business Services, Inc.$77K
  • Medtronic$55K
  • Abbott$36K
  • plus $45K from 32 others

What the payments were for

  • Consulting fees$265,97939%
  • Speaking & faculty fees$309,57445%
  • Grants$2,0000%
  • Travel & lodging$73,02811%
  • Food & beverage$40,0556%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,099,858 in reported general payments places this provider in the 95th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$785,775
Medicare patients
1,033
Services billed
7,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban357$405,067
XareltoRivaroxaban108$120,030
EntrestoSacubitril/Valsartan70$92,918
JardianceEmpagliflozin32$37,294
FarxigaDapagliflozin Propanediol11$18,635
Amiodarone Hcl149$7,031
Metoprolol Succinate340$5,545
Dofetilide18$4,915
Diltiazem 12hr ErDiltiazem Hcl14$3,304
Flecainide Acetate86$2,797
Ranolazine ErRanolazine17$2,558
Losartan Potassium120$1,309
Carvedilol130$1,298
Atorvastatin Calcium115$1,098
Ezetimibe57$1,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$405,067357 claims
Johnson & JohnsonXarelto$160$120,030108 claims
NovartisEntresto$124$92,91870 claims
AstraZenecaFarxiga$15$18,63511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →